Rapport Therapeutics Down Over 16%, on Pace for Largest Percent Decrease in Over a Year -- Data Talk
Dow Jones2026/09/23 18:01Rapport Therapeutics, Inc. (RAPP) is currently at $34.56, down $6.91 or 16.66%
--Would be lowest close since May 19, 2026, when it closed at $34.37
--On pace for largest percent decrease since Sept. 10, 2025, when it fell 20.09%
--Currently down three of the past four days
--Down 28.99% month-to-date; on pace for worst month since Feb. 2025, when it fell 38.88%
--Up 13.91% year-to-date
--Down 34.17% from its all-time closing high of $52.50 on Aug. 26, 2026
--Up 28.19% from 52 weeks ago (Sept. 24, 2025), when it closed at $26.96
--Down 34.17% from its 52-week closing high of $52.50 on Aug. 26, 2026
--Up 41.81% from its 52-week closing low of $24.37 on Nov. 14, 2025
--Traded as low as $34.40; lowest intraday level since June 11, 2026, when it hit $33.51
--Down 17.06% at today's intraday low; largest intraday percent decrease since Sept. 10, 2025, when it fell as much as 20.23%
All data as of 1:58:13 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
September 23, 2026 14:01 ET (18:01 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.